Colson P, Ryckwaert F, Ribstein J, Mann C, Dareau S
Service d'Anesthésie Réanimation B, Hopital Arnaud de Villeneuve, Montpellier, France.
Acta Anaesthesiol Scand. 1998 Oct;42(9):1114-9. doi: 10.1111/j.1399-6576.1998.tb05387.x.
Favourable outcome of phaeochromocytoma surgery requires that paroxysmal hypertension and arrhythmia be controlled, and that hypotension be prevented. Is nicardipine, a calcium channel blocking drug, always adequate?
Nineteen consecutive patients underwent surgery for phaeochromocytoma. Management was standardised with regards to anaesthesia and antihypertensive treatment. Nicardipine was used as a vasodilator and was given in order to maintain systemic vascular resistance lower than 1600 dyn.s.cm-5.
Hypertension did not occur at any time during surgery in 6/19 patients. Blood pressure rose acutely in 3/19 patients at the time of tracheal intubation or surgical approach to the tumour, and was controlled by increased depth of anaesthesia. Hypertensive episodes occurred in 11/19 patients during tumour manipulation. Nicardipine always succeeded in maintaining low systemic vascular resistance but its dosage varied widely between patients (0.5 to 70 mg), a fact that may be accounted for by the striking intersubject variability of haemodynamic behaviour during surgery. In 7/11 patients, despite nicardipine treatment, sustained increase in blood pressure persisted with increased cardiac index, but low systemic vascular resistance. Following tumour removal, transient serious hypotension (MAP < 60 mmHg) occurred in 4 patients, and was corrected by fluid volume expansion. Perioperative incidence of hypertension or hypotension was not related to preoperative clinical status.
Adequate management of patients operated upon for phaeochromocytoma requires invasive monitoring, since the mechanisms underlying hypertensive crises are heterogeneous with regards to systemic vascular resistance and not predictable from preoperative data. Nicardipine provides a good control of vasoconstriction during phaeochromocytoma surgery with limited risk of serious hypotension after tumour removal.
嗜铬细胞瘤手术的良好预后要求控制阵发性高血压和心律失常,并预防低血压。钙通道阻滞剂尼卡地平是否始终足够有效?
19例连续的患者接受了嗜铬细胞瘤手术。麻醉和抗高血压治疗进行了标准化管理。尼卡地平用作血管扩张剂,给药以维持体循环血管阻力低于1600达因·秒·厘米⁻⁵。
19例患者中有6例在手术期间任何时候均未发生高血压。19例患者中有3例在气管插管或手术接近肿瘤时血压急性升高,通过加深麻醉得以控制。19例患者中有11例在肿瘤操作期间发生高血压发作。尼卡地平始终成功维持低体循环血管阻力,但其剂量在患者之间差异很大(0.5至70毫克),这一事实可能是由于手术期间血流动力学行为在个体间存在显著差异所致。在11例患者中的7例中,尽管使用了尼卡地平治疗,但血压持续升高,同时心脏指数增加,但体循环血管阻力较低。肿瘤切除后,4例患者出现短暂性严重低血压(平均动脉压<60 mmHg),通过扩容得以纠正。围手术期高血压或低血压的发生率与术前临床状况无关。
嗜铬细胞瘤手术患者的充分管理需要有创监测,因为高血压危象的潜在机制在体循环血管阻力方面是异质性的,且无法根据术前数据预测。尼卡地平在嗜铬细胞瘤手术期间能很好地控制血管收缩,肿瘤切除后发生严重低血压的风险有限。